Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Stock Quote Today & Recent News Oncotelic Therapeutics Inc OTLC

Healthcare Biotechnology
Oncotelic Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing drugs for the treatment of orphan oncology indications, developing antisense and small molecule injectable drugs for the treatment of cancer. The Company’s pipeline includes OT-101, CA4P and Oxi4503. OT-101 is antisense against TGF-2 for the treatment of solid tumors with focus on... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (OTCQB:OTLC)

Linkage of Cancer and Lupus in Gliomas Patients

GlobeNewswire March 25, 2024

Invitation to Participate in STOP-PC Clinical Trial

GlobeNewswire March 4, 2024

Oncotelic Therapeutics Announces Clinical Linkage of TGFB2 and IFNGR2 in Pediatric DMG Patients

GlobeNewswire January 16, 2024

Oncotelic Therapeutics Announces Opening of GMP Manufacturing Plant

GlobeNewswire December 18, 2023

Oncotelic Therapeutics Announces CEO To Discuss Proprietary AI Technology at Ibero-American Chatbot Summit.

GlobeNewswire November 28, 2023

Oncotelic Reports Q3 2023 Compared to Q3 2022 Financial Results

GlobeNewswire November 15, 2023

Oncotelic Therapeutics, Inc. Awarded Top Cancer Immunotherapy Solutions Provider 2023

GlobeNewswire August 25, 2023

Sapu BioScience and Cromos Pharma initiating P201 - A Registrational trial for OT-101 in Pancreatic Cancer

GlobeNewswire August 23, 2023

Oncotelic Launches PR Chatbot

GlobeNewswire June 12, 2023
View More News ››

Opinion & Analysis (OTCQB:OTLC)

No current opinion is available.
View More Opinion ››

Bullboard Posts (OTCQB:OTLC)

Oncotelic Announces Release of Pet2DAO Tokens (PDAO)

Oncotelic Announces Release of Pet2DAO Tokens (PDAO) - Oncotelic Therapeutics (OTC:OTLC) - Benzinga
DepartedSe7en - April 5, 2023

Oncotelic Awarded BARDA Funding for Development of OT-101

Oncotelic Awarded BARDA Funding for Development of OT-101 for long COVID: https://www.yahoo.com/now/oncotelic-awarded-barda-funding...
DepartedSe7en - October 17, 2022

Oncotelic Announces Pipeline Presentation and IPO Update of

Oncotelic Announces Pipeline Presentation and IPO Update of Sapu Therapeutics at the 2022 BIO International Convention: https:/...
DepartedSe7en - June 15, 2022

RE:ONCOTELIC PROVIDES Q1 2022 FINANCIAL RESULTS COMPARED TO Q1

finally a US company posting on a day of trading , not like 5 pages of CDN posts for tomorrow, 
satchmo6 - May 23, 2022

ONCOTELIC PROVIDES Q1 2022 FINANCIAL RESULTS COMPARED TO Q1

ONCOTELIC PROVIDES Q1 2022 FINANCIAL RESULTS COMPARED TO Q1 (globenewswire.com)
DepartedSe7en - May 23, 2022

Oncotelic Appoints Fatih Uckun, M.D., Ph.D., as CMO

Oncotelic Appoints Fatih Uckun, M.D., Ph.D., as Chief Medical Officer: https://oncotelic.irpass.com/Oncotelic-Appoints-Fatih...
DepartedSe7en - May 4, 2022
View more Bullboard ››

Delphx Capital Markets Inc.

Delphx Capital Markets Inc.

DelphX is a technology and financial services company focused on developing and distributing the next generation of ...
View More »